The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi that the agency recommended for approval in November for some patients with early Alzheimer's disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,